In April 2024, the Alethium team attended the World Orphan Drug Congress in Boston to engage with industry leaders on orphan drug research and improving access to therapies for rare disease patients.

Our team resonated with panel discussions emphasizing the importance of robust science, resilience, and innovation, as well as the need for firsthand knowledge of the unique challenges facing rare disease patients, families and caregivers.

Our agile team built the Alethium eClinical Platform to meet the demands of complex study protocols. By addressing specific patient and caregiver needs – from integrated televisits and seamless translations – we are dedicated to making rare disease studies globally accessible at exceptional speed, lower cost, and minimal risk.

Thank you to everyone who made the conference an impactful event. Together, we’re advancing toward a future where rare diseases are better understood and managed.